{"filing":{"accession_number":"0001554855-26-001607","cik":"0000888721","ticker":"TRIB","company_name":"TRINITY BIOTECH PLC","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"MainDocument.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/888721/000155485526001607/MainDocument.htm"},"events":[{"id":19349,"run_id":17409,"accession_number":"0001554855-26-001607","anchor_item_number":"EX-99.1","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Trinity Biotech announced a plan to change its ADS ratio from 1:20 to 1:600 (equivalent to a 1-for-30 reverse ADS split), effective July 24, 2026. The stated purposes are to regain Nasdaq compliance with the $1.00 minimum bid price requirement and to broaden the investor base. While this is a material capital structure event affecting all ADS holders, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a governance vote, not a periodic report). The event is clearly material to investors as it affects trading mechanics and compliance status, but the domain is structural/capital-markets rather than operational, financial, legal, or governance in the traditional sense.","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18413,"accession_number":"0001554855-26-001607","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Trinity Biotech announced a plan to change its ADS ratio from 1:20 to 1:600 (equivalent to a 1-for-30 reverse ADS split), effective July 24, 2026. The stated purposes are to regain Nasdaq compliance with the $1.00 minimum bid price requirement and to broaden the investor base. While this is a material capital structure event affecting all ADS holders, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a governance vote, not a periodic report). The event is clearly material to investors as it affects trading mechanics and compliance status, but the domain is structural/capital-markets rather than operational, financial, legal, or governance in the traditional sense.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:01:57.622007+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18413,"accession_number":"0001554855-26-001607","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Trinity Biotech announced a plan to change its ADS ratio from 1:20 to 1:600 (equivalent to a 1-for-30 reverse ADS split), effective July 24, 2026. The stated purposes are to regain Nasdaq compliance with the $1.00 minimum bid price requirement and to broaden the investor base. While this is a material capital structure event affecting all ADS holders, it does not fit neatly into the standard taxonomy categories (not a dilutive issuance, not a governance vote, not a periodic report). The event is clearly material to investors as it affects trading mechanics and compliance status, but the domain is structural/capital-markets rather than operational, financial, legal, or governance in the traditional sense.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:01:57.622007+00:00","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-22"}]}